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OBJECTIVE: To validate the importance of the angiotensin II receptor isotypes and the lymphatic vessels in
systemic sclerosis and idiopathic pulmonary fibrosis.
METHODS: We examined angiotensin II type 1 and 2 receptors and lymphatic vessels in the pulmonary tissues
obtained from open lung biopsies of 30 patients with systemic sclerosis and 28 patients with idiopathic
pulmonary fibrosis. Their histologic patterns included cellular and fibrotic non-specific interstitial pneumonia
for systemic sclerosis and usual interstitial pneumonia for idiopathic pulmonary fibrosis. We used
immunohistochemistry and histomorphometry to evaluate the number of cells in the alveolar septae and the
vessels stained by these markers. Survival curves were also used.
RESULTS:Wefounda significantly increasedpercentageof septal and vessel cells immunostained for theangiotensin
type 1 and2 receptors in the systemic sclerosis and idiopathic pulmonary fibrosis patients comparedwith the controls.
A similar percentage of angiotensin 2 receptor positive vessel cells was observed in fibrotic non-specific interstitial
pneumonia andusual interstitial pneumonia. A significantly increasedpercentageof lymphatic vesselswas present in
the usual interstitial pneumonia group comparedwith the non-specific interstitial pneumonia and control groups. A
Cox regression analysis showed a high risk of death for the patients with usual interstitial pneumonia and a high
percentage of vessel cells immunostained for the angiotensin 2 receptor in the lymphatic vessels.
CONCLUSION:We concluded that angiotensin II receptor expression in the lung parenchyma can potentially control
organ remodeling and fibrosis, which suggests that strategies aimed at preventing high angiotensin 2 receptor
expression may be used as potential therapeutic target in patients with pulmonary systemic sclerosis and idiopathic
pulmonary fibrosis.
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& INTRODUCTION
Diffuse parenchymal lung diseases (DPLD), also known
as interstitial lung diseases (ILD), encompass a heteroge-
neous group of disorders, including idiopathic pulmonary
fibrosis (IPF) and systemic sclerosis (SSc). These disorders
result from the remodeling of the lung parenchyma by
varying inflammation and fibrosis patterns that frequently
affect the alveolar septae and vessels and their respective
epithelial, endothelial and muscular linings (1). However,
patients with interstitial pneumonia associated with SSc
have a better prognosis than patients with idiopathic
interstitial pneumonia (2-6) because of their increased
response to immunosuppressive therapies and the preva-
lence of septal cellular thickening, which is associated with
the pattern of nonspecific interstitial pneumonia (NSIP)
(7-12). The prognosis is not as good for IPF patients with a
pattern of usual interstitial pneumonia (UIP) (12). Thus,
there is great interest in developing methods that can
identify the mechanisms of parenchymal and vascular
remodeling. We must identify these pathogenic mechanisms
to avoid destroying the lungs and to provide effective
treatment.
Many studies have investigated the parenchymal and
vascular remodeling markers in DPLD to identify the
mechanisms behind the disease progression and shortened
survival rates (13-17). Because epithelial and endothelial
cells and fibroblasts represent an abundant and functionally
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important group of cells in lung fibrosis (18), a group of
angiotensins that exert biological effects on these cell types
have been described (19) and, therefore, may be targeted as
potentially useful modulators of organ remodeling and
fibrosis (20-22). Of these angiotensins, angiotensin II (ANG
II) has shown promise. ANG II is generated by the cleavage
of angiotensin I by the angiotensin-converting enzyme
(ACE). ANG II binds to and acts via 2 high-affinity receptor
isotypes, the angiotensin II type-1 (AGTR-1) and type-2
(AGTR-2) receptors, both of which belong to the
7-transmembrane G protein–coupled receptor family
(23,24). In some studies, AGTR-2 has been detected in
different adult human cells and in fetal tissue, in which it
seems to play a major role during embryonic development
(25-27). Other studies have shown that AGTR-2 inhibits or
counteracts the AGTR-1 mediated effects by directly
interacting with AGTR-1 (28), but there has been uncertainty
about the signaling pathway activated by AGTR-2 (29-31).
These studies have indicated that the ACE-ANGII-AGTR
axis contributes to the fibrotic response in the lung;
however, the role that the AGTRs play in developing lung
fibrosis in IPF and SSc remains unclear. To validate the
importance of the ACE-ANGII-AGTR axis, to explore the
quantitative relationship between this factor and patient
outcomes and to examine the relationship between AGTRs
and other parenchymal and vascular factors, we studied
these markers in 30 SSc and 26 IPF patients.
& PATIENTS AND METHODS
Between January 2002 and July 2004, 30 consecutive
patients with SSc and ILD (identified using high-resolution
computed tomography [HRCT]) and 26 IPF patients under-
went open lung biopsies at the Clinical Hospital, University
of Sa˜o Paulo Medical School (1,32). The median patient age
was 64 years (range, 57-71 years) for IPF (16 men, 10
women) and 45 years (range, 35-53 years) for SSc (all
women). All patients fulfilled the diagnostic and subtype
criteria for SSc (33,34) and IPF (35,36). Open lung biopsy
was performed using formal thoracotomy, thereby avoiding
honeycombing areas. The 56 patients provided written
informed consent (protocol number 0960/08), and the study
was approved by the local ethics committee. The patients’
clinical records were analyzed. The HRCT and pulmonary
function test (PFT) were performed up to 3 months before
the biopsies. The pulmonary function tests included the
forced expiratory volume in 1 s (FEV1), forced vital capacity
(FVC), FEV1/FVC ratio 100, total lung capacity (TLC) and
residual volume and carbon monoxide transfer factor
(DLCO). The TLC, residual volume and residual volume/
TLC percentages were measured using the helium dilution
method with a MasterScreen apparatus (Erich Jaeger
GmbH, Wu¨rzburg, Bavaria, Germany), and the DLCO and
DLCO/alveolar volume were measured using the single
breath-holding helium dilution method (37). The lung
function measurements are reported as percentages of the
predicted values. The cardiac parameters of these patients
were normal. The HRCTs were performed using 1.0- or 1.5-
mm-thick sections with patients in the supine position and
with full inspiration at 10-mm intervals. A specialized chest
radiologist and a pneumologist analyzed the images at 3
pre-established levels (i.e., the trachea, carina and pulmon-
ary veins) for the presence of any signs of ILD, such as
ground glass, consolidation, reticular opacities, honeycomb-
ing and bronchiectasis.
Histological analysis
The pulmonary tissue was fixed in 10% neutral buffered
formalin and embedded in paraffin. Thin sections were
stained with hematoxylin and eosin. Additional subserial
sections from the paraffin blocks were used for the
immunohistochemistry. Two pathologists who specialize
in lung diseases and were blinded to the clinical aspects of
the patients classified the lung specimens according to the
new ILD classification consensus (1). The pathologists made
their final diagnoses by consensus. UIP, the histologic
pattern of IPF, was characterized by a patchy subpleural
and paraseptal distribution of the parenchymal injury.
Temporal heterogeneity was observed at low magnifica-
tion, with areas of normal lung parenchyma alternating
with alveolar collapse, interstitial mononuclear infiltrates,
septal fibromyxoid tissue (fibroblastic foci) and honeycomb
lung. All SSc patients had histologic patterns that were
consistent with non-specific interstitial pneumonia, as
defined by temporally homogeneous septal inflammatory
thickening and interstitial fibrosis. Normal lung tissue,
which was obtained from 10 individuals (3 males and 7
females; median age 47 years, range 31 to 60 years) who
had died suddenly from non-pulmonary causes, served as
the control.
Immunohistochemistry
A standard peroxidase technique was used with Harris’s
hematoxylin as the counterstain to identify AGTR-1 and
AGTR-2 expression in the alveolar septae and vascular wall
cells. D2-40 was used to identify lymphatic vessels in the
control, IPF-UIP pattern (normal, collapsed and fibroblastic
foci areas) and SSc-NSIP pattern lungs. Biotinylated goat
polyclonal antibodies were used. Anti-AGTR-1, anti-AGTR-
2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA)
and anti-D2-40 (Signet Laboratory Inc., USA) antibodies
were incubated with the tissue sections at 1:50, 1:50 and
1:100 dilutions, respectively. A Max Polymer Novolink
amplification kit (Leica, Newcastle Inc., UK) was used for
signal amplification, and 3.39-diaminobenzidine tetrachlor-
ide (0.25 mg dissolved in 1 mL 0.02% hydrogen peroxide)
was used as a precipitating substrate for signal detection.
The specificity of the primary antibodies was confirmed by
the appropriate reagent controls (omitting the primary
antibody or substituting non-immune serum for the
primary antibody in the staining protocol), which revealed
no staining. The positive expression of AGTR-1, AGTR-2
and D2-40 was indicated by brown cytoplasmic staining of
the cells.
Histomorphometry
The area fraction occupied by AGTR-1/AGTR-2+ cells in
the alveolar septae and vascular walls and lymphatic vessels
along the peripheral and periaxial interstitium was deter-
mined with a point-counting procedure (38). We used a 100-
point grid with a known area (187.500 mm2 at 4006
magnification) attached to the microscope eyepiece (38).
Ten fields were chosen from across multiple sites, account-
ing/adjusting for the cellularity or number of positively
immunostained cells per connective tissue area (38). Thus,
the septal area in each field was determined according to the
number of points falling within the positive cells in the field
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of view (as a proportion of the total grid area). Afterwards,
the number of positive cells within the septal area was
counted. The immunostaining cellularity was determined as
the number of positive cells in each field divided by the
septal area. The final results were expressed as the
mean¡standard deviation (SD) of the lung specimens for
each patient in 10 random, non-coincident microscopic
fields.
To control for variation in the scoring between our 2
histologists (ERP and VLC), 20% of the stained slides were
independently scored by both observers. The coefficient of
variance between the cell counts for the 2 observers was,5%.
Statistical analysis
The data are reported as the means¡SD. The statistical
analyses were performed using an analysis of variance
(ANOVA) followed by the appropriate post hoc tests,
including Bonferroni correction and Student’s t-test for
comparisons between 2 groups. The survival curves were
determined using the Kaplan-Meier method, and the risk of
death was estimated using a Cox regression analysis. The
statistical program SPSS, Inc. (USA) was used, and p,0.05
was considered to be significant.
& RESULTS
Clinical features
The clinical features of the 56 patients included in this
study are shown in Table 1. All studied patients showed a
restrictive lung function pattern that was characterized by a
decrease in TLC (the mean values were 81% of that
predicted for SSc-NSIP and 78% of that predicted for IPF-
UIP) and an increased FEV 1/FVC ratio/100 (the mean
value was 107% of that predicted for SSc-NSIP vs. 90% of
that predicted for IPF-UIP). The mean predicted DLCO
values were significantly decreased in the IPF-UIP patients
(55%) compared with the SSc-NSIP (66%) patients, and they
were significantly greater when comparing the DLCO/VA
in the IPF-UIP (47%) vs. the SSc-NSIP (77%) patients. No
difference was found in the FEV1, FCV, TLC and RV values
between the SSc-NSIP and IPF-UIP groups (Table 1).
Angiotensin II type 1 and 2 receptors
Alveolar septae and vessels from the normal control lungs,
NSIP and UIP histologic patterns are shown in Figure 1
(immunostained with the AGTR-1 and AGTR-2 antibodies).
Different immunostaining intensity was observed in the
epithelial, endothelial, myofibroblast and smooth muscle
cells from the alveolar septae and vessels in the SSc-NSIP
(cellular SSc-NSIP and fibrotic SSc-NSIP) and IPF-UIP groups
compared to the normal control lungs. Table 2 summarizes
the morphometric results. A significantly higher percentage
of the septal and vessel cells immunostained for AGTR-1/
AGTR-2 in the cellular SSc-NSIP, fibrotic SSc-NSIP and IPF-
UIP lungs was observed compared to the controls. In the SSc-
NSIP and IPF-UIP lungs, a similar proportion of the septal
cells immunostained for AGTR-1 was observed, except for
the IPF-UIP lungs, in which the AGTR-2 immunoreactivity
represented a significantly reduced proportion of the septal
cells compared to the SSc-NSIP lungs. Of equal significance
was the increased percentage of the vessel cells that were
immunostained for AGTR-1 in the cellular SSc-NSIP and IPF-
UIP lungs. Concerning AGTR-2, a similar percentage of the
vessel cells was present in the fibrotic SSc-NSIP and IPF-UIP
lungs. When we compared the total cellular expression of
AGTR-1 in the SSc-NSIP and IPF-UIP groups, a similar
proportion was observed; however, both were increased
compared to the control group (Figure Q), except for the IPF-
UIP lungs, in which the total cellular AGTR-2 expression had
a significantly smaller proportion than that of the SSc-NSIP
pattern lungs (Figure R).
Distribution of lymphatic vessels
Figure 2 shows the peripheral, interlobular and peri-
bronchovascular lymphatic vessels from the normal control
lungs and the SSc-NSIP and IPF-UIP histologic patterns,
immunostained for D2-40. A different proportion of the
lymphatic vessels in the peripheral, interlobular and
peribronchovascular interstitium was visualized in the
SSc-NSIP (cellular SSc-NSIP and fibrotic SSc-NSIP) and
IPF-UIP lungs compared to the control lungs. Table 2
summarizes the morphometric results. In the peripheral,
interlobular and peribronchovascular interstitium of the
IPF-UIP group, the lymphatic vessels showed a significantly
increased area compared to the SSc-NSIP lungs (Figure G).
A significantly higher percentage of lymphatic vessels was
present in the peripheral, interlobular and periaxial inter-
stitium of the IPF-UIP pattern compared to the SSc-NSIP
histologic pattern (Figure H).
Pulmonary function tests
A significant inverse association was found between the
vascular AGTR-2 and DCLO/VA (R = -0.74, p = 0.001) in the
SSc-NSIP and (R = -0.78, p = 0.001) UIP groups. Equally
significant was the negative association between the
lymphatic vessel area in SSc-NSIP and the predicted values
of DLCO (R = -0.53, p = 0.04).
Survival analysis
Nineteen patients died during the 180-month follow-up
period (5 SSc-NSIP and 14 IPF-UIP). A preliminary
examination of the Kaplan-Meier survival curves showed
that in this study, the patients with the SSc-NSIP pattern
with percentages of vessel cells immunostained for AGTR-1
that were ,2.49% and AGTR-2 percentages ,7.46% had
Table 1 - Clinical data of the patients with systemic
sclerosis and idiopathic pulmonary fibrosis.
SSc-NSIP
(n= 30) IPF-UIP (n = 26) p-value
Age, years 45¡8 64¡7 ,0.001
Sex (female/male) 30 10/16 1.2
Spirometry
FEV1 (% predicted) 70¡13.8 76¡20.01 0.23
FVC (% predicted) 65¡13.8 69¡16.8 0.35
FEV1/FVC 107¡8.69 90¡18.7 ,0.001
TLC (% predicted) 81¡11.5 78¡21.9 0.64
RV (% predicted) 117¡35.5 101¡62.04 0.36
DLCO (% predicted) 66¡21.6 55¡19.1 0.01
DLCO/VA (% predicted) 77¡35.2 47¡22.74 0.008
The data are expressed as the means¡SD or as counts (percentages);
p,0.05 was significant.
Abbreviations: NSIP, non-specific interstitial pneumonia; UIP, usual
interstitial pneumonia; FEV1, forced expiratory volume in 1 s; FVC, forced
vital capacity; TLC, total lung capacity; RV, residual volume; DLCO,
diffusing capacity of the lung for carbon monoxide; VA, alveolar volume.
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higher survival rates than the patients with percentages of
vessel cells immunostained for AGTR-1 that were .2.49%
and AGTR-2 percentages .7.46. The multivariate analyses
by the Cox regression model showed statistical significance
(log-likelihood = 59.39, p,0.0001) with a high risk of death
for the patients with the IPF-UIP pattern (p= 0.01) and a
high percentage of vessel cells immunostained for the
AGTR-2 and lymphatic vessels (Table 3).
Figure 1 - Cellular expression of the angiotensin II type 1 receptor (AGTR-1) and AGTR-2 divided in septal areas and intrapulmonary
vessels from normal control lungs, systemic sclerosis (SSc) and idiopathic pulmonary fibrosis (IPF). In (A) and (B), we observe a diffuse
and minimal AGTR-1 (arrows) expression in the alveolar septal areas and in the intrapulmonary vessels of the controls. The AGTR-1
expression shows greater increases in the thickened alveolar septal region from the cellular SSc-NSIP (arrows, E) than in the fibrotic SSc-
NSIP (arrows, I). In the intrapulmonary vessels, the expression of AGTR-1 (arrows) is minimal and similar in both groups (cellular SSc-
NSIP, F and fibrotic SSc-NSIP, J). Increased expression of AGTR-1 (arrows) is observed in the septal areas (M) and intrapulmonary vessels
(N) of IPF-UIP. In (C) and (D), we observed AGRT-2 (arrows) expression in the septal areas and intrapulmonary vessels from the controls.
In (G) and (K), we observed a similar expression of AGTR-2 (arrows) in the septal areas of cellular and fibrotic SSc-NSIP. Increased
expression of AGTR-2 (arrows) is observed in the intrapulmonary vessels of fibrotic SSc-NSIP (L) compared to cellular SSc-NSIP (H). The
expression of AGTR-2 (arrows) is more evident in the septal areas of IPF-UIP (O) than in the intrapulmonary vessels (P) of this histologic
pattern. Q and R show the total values of AGTR-1 and AGTR-2 and the results analyzed by a one-way ANOVA with the Bonferroni
multiple comparisons test for the control, SSc-NSIP and IPF-UIP groups. (*) Significantly higher AGTR-1 expression was observed in the
SSc-NSIP and IPF-UIP lungs compared with the control group (p=0.001 and p=0.001, respectively). A similar situation was observed
with AGTR-2 expression from the SSc-NSIP and IPF-UIP patterns compared to the control group (p,0.001 and p,0.001, respectively). ({)
Significantly higher expression of AGTR-2 in the SSc-NSIP group was observed when compared with the IPF-UIP group (p=0.04) by
Student’s t-test.
Table 2 - Summary of the morphometric resultsa.
Variables Control Cellular SSc-NSIP Fibrotic SSc-NSIP SSc-NSIP UIP
Septal AGTR-1 1.45¡1.02 10.72¡6.20 12.18¡8.00 11.41¡6.97 10.10¡22.23
Vascular AGTR-1 1.06¡1.03 4.36¡5.35 0.51¡1.15 2.53¡4.33 2.13¡1.64
Septal AGTR-2 0.03¡0.02 12.75¡8.05 12.78¡6.96 12.77¡7.36 7.78¡4.31
Vascular AGTR-2 0.01¡0.04 1.26¡1.35 6.91¡4.64 3.83¡4.30 6.06¡4.66
Total AGTR-1 1.25¡0.84 7.54¡4.49 6.34¡3.96 6.97¡4.18 6.26¡10.93
Total AGTR-2 0.02¡0.02 6.51¡3.88 9.85¡5.09 8.18¡4.73 6.38¡3.63
Lymphatic density 1.68¡0.38 2.72¡0.62 2.92¡0.69 2.80¡0.65 3.73¡1.19
Lymphatic area 2.81¡0.90 4.28¡1.32 4.33¡0.64 4.25¡1.08 5.52¡2.24
aThe units of ‘‘% of points’’ indicate the number of points overlying the phenomena of interest divided by the total number of points overlying the septae
and vessels. In morphometry, this process is called a point fraction and is often symbolized as Pp. The Pp has been shown to approximate the volume
fraction or Vv.
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Figure 2 - D2-40 cell expression in the lymphatic vessels of the normal control lungs, systemic sclerosis (SSc) and idiopathic pulmonary
fibrosis (IPF). The lymphatic vessels (arrows) were observed in the sub pleural (A) and interlobular septal interstitium (B) in the control
lungs. In cellular SSc-NSIP, the lymphatic vessels (arrows) were observed in the thickened alveolar septal region (C) and were infrequent
compared to the fibrotic SSc-NSIP pattern (arrows, D). In the UIP pattern, we observed a higher proportion of lymphatic vessels (arrows)
in the interlobular and subpleural spaces (E and F). G and H represent the total values of the lymphatic dilatation and density, and the
results analyzed by the one-way ANOVA followed by the Bonferroni multiple comparisons test for the control, SSc-NSIP and IPF-UIP
groups. (*) A significantly increased lymphatic dilatation (G) was observed in the IPF-UIP group compared to the SSc-NSIP (p=0.01) and
control (p=0.01) groups. Similarly, a significantly higher lymphatic density (H) was observed in the IPF-UIP group compared to the SSc-
NSIP (0.02) and control (0.01) groups.
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& DISCUSSION
Unlike SSc-NSIP, the likely reason that IPF-UIP patients
do not respond to immunosuppressive therapies and their
clinical course is marked by inexorable deterioration is the
imbalance between parenchymal and vascular remodeling.
Therefore, it is important to determine whether additional
histological details can help us understand the clinical
differences between these diseases. After pulmonary injury,
parenchymal and vascular remodeling contribute to
increased pulmonary epithelial and endothelial permeabil-
ity. This early phase is followed by a subacute fibroproli-
ferative phase, which may allow repair of the injured lung
or may result in progressive obliteration of the interstitial,
alveolar and vascular compartments of the lung through a
fibroproliferative process that may be established by 24 h
after the injury (39).
Recent studies have shown that ANG II contributes to
pulmonary fibrosis progression, which is evidenced not
only by its potent vasoconstrictor activity but also by its
influence on organ remodeling and fibrosis (20,21,22). The
AGTR-1 and AGTR-2 binding of ANG II is facilitated by the
cleavage of ANG I by the ACE. Both receptors belong to the
7-transmembrane G protein–coupled receptor family
(23,24). Whereas most of the ANG II-mediated effects, such
as cell growth, inflammation or extracellular matrix synth-
esis, have been shown to be mediated via AGTR-1, the
function of AGTR-2 has been less clearly investigated
(40,41). During the development of fibrosis, AGTR expres-
sion undergoes an expression shift in favor of higher AGTR-
2 levels, thereby tilting the cellular response to ANG II
(42-44). Thus, for all these reasons, we should not be
surprised to learn that immunohistochemical staining for
AGTRs provides important information about the organ
remodeling process in diffuse parenchymal lung diseases,
and our results now confirm the pathogenetic importance of
AGTRs in IPF and SSc.
We found a significantly greater percentage of septal and
vessel cells immunostained for AGTR-1 in SSc-NSIP and
IPF-UIP compared with the normal lung. In addition, SSc-
NSIP and IPF-UIP had a similar proportion of septal cells
immunostained for AGTR-1. We also found an increased
percentage of vessel cells immunostained for AGTR-1 in
cellular SSc-NSIP and IPF-UIP. Previous reports in the
literature have shown the potential role of ANG II in
experimental lung fibrosis and in IPF (42-44), while the
potency of AGTR-1 in fostering lung fibrosis has been
previously demonstrated in multiple in vitro cell culture
conditions as well as in vivo animal models (45,42). In
experimental animal models of lung fibrosis, using bleo-
mycin exposure or radiation, the fibrotic response was
attenuated by the ACE inhibitors and by specific AGTR-1
antagonism (45,46). Studies of the inhibition of the ANG II
pathway have demonstrated opposing results. Some studies
have shown beneficial results and blocked the fibrosis,
principally in bleomycin-induced pulmonary fibrosis (47);
others have failed to document a beneficial effect of the
ANG II blockade in experimental models of lung fibrosis,
indicating that the fibrotic disease process is dependent not
only on AGTR-1 activity (48). We found that a small
percentage of vessel cells in SSc-NSIP are AGTR-1+. In
contrast to the data available for AGTR-1, the function of
AGTR-2 is much less well explored. In our study, there was
an increased percentage of vessel cells immunostained for
AGTR-2 in SSc-NSIP and IPF-UIP, suggesting an important
role in the pathogenesis of these disorders. In heart tissue,
the AGTR-2 is considered to be a neutralizer, modulating
the actions of AGTR-1 (28,29), but many signaling mechan-
isms and receptor functions are unclear, particularly the role
of AGTR-2 in pulmonary fibrosis.
We also found a significantly higher percentage of
lymphatic vessels in the peripheral, interlobular and
periaxial interstitium of IPF-UIP compared with the SSc-
NSIP histologic pattern. In IPF-UIP, the lymphatic vessels
showed a significantly increased area compared with SSc-
NSIP. The lymphatic vessels contribute to fibrosis matura-
tion and scar formation through the drainage of excessive
proteins and fluid during fibrosis (49). In the present study,
D2-40+ lymphatics were abundant in the peripheral,
interlobular and peribronchovascular interstitium. Pre-
vious studies performed by our group have shown that
the lymphatic vessels play an important role in early
remodeling in the development of pulmonary fibrosis (50).
The current study clearly demonstrated that the lymphatic
vessels were poorly detected in the affected areas of early
remodeling, such as cellular SSc-NSIP, compared to the
fibrotic SSc-NSIP and IPF-UIP patterns.
Our study has clinical and functional importance. A
significant inverse association was found between vascular
AGTR-2 and DCLO/VA in the SSc-NSIP and IPF-UIP
groups. Of equal significance was the negative association
between the lymphatic vessel area in SSc-NSIP and the
predicted values of DLCO. To establish the relevance of
these findings to disease progression in the patients, the
AGTRs were evaluated as a function of survival (controlled
for age) in the IPF-UIP and SSc-NSIP histologic patterns.
The multivariate analyses using the Cox regression model
showed a high risk of death for the patients with the IPF-
UIP pattern presenting a high percentage of vessel cells
immunostained for AGTR-2 in the lymphatic vessels.
We concluded that the AGTRs and lymphatic vessels in
the lung parenchyma offer the potential to control the organ
Table 3 - Cox proportional hazards regression to ascertain the individual contribution of the histological patterns (NSIP
and UIP) and the morphological factors associated with survival and to compare the adjusted survival between the
groups (-2 log-likelihood=59.93; Chi-squared=40.10; p,0.001).
b SE Wald test p-value Exp (b) 95.0% CI for Exp (b)
Lower Upper
NSIP pattern -12.70 182.18 5.97 0.94 0.00 0.00 0.60E149
UIP pattern -1.60 0.65 5.97 0.01 0.20 0.56 0.78
AGTR2 vascular 0.26 0.89 9.23 0.002 1.30 1.10 1.55
Lymphatic density -1.20 0.25 6.92 0.008 0.297 0.122 0.73
b=beta coefficient; SE = standard error; Exp (b) = exponential beta; CI = Confidence interval.
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remodeling and fibrosis involved in SSc-NSIP and IPF-UIP
progression, which suggests that strategies aimed at
preventing high AGTR synthesis and low lymphangiogen-
esis may have a greater impact on SSc and IPF. Further
study using a randomized and prospective trial is necessary
to finalize this conclusion.
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